Paulo Costa

Paulo Costa joined the CorMedix board in September 2020. Mr. Costa currently serves as Chairman of the Board of MacroGenics, a public late stage biopharma company focused on oncology. In addition, he served as Chairman of Amylin Pharmaceuticals, a commercial stage biopharma company, until its sale to Bristol-Myers Squibb and AstraZeneca in a $7 billion transaction in 2012. Prior to his retirement, Mr. Costa served in senior leadership roles at Novartis, including President and CEO of Novartis US Corporation from 2005 to 2008 and President and CEO of Novartis Pharmaceutica US and Head of Americas from 1999 to 2005. Prior to joining Novartis, Mr. Costa spent 30 years at Johnson & Johnson including as President of Janssen Pharmaceutica, Inc. During the course of his career, he helped launch and grow a broad range of primary and specialty care products and has built and shaped pharmaceutical sales forces globally. Mr. Costa received his undergraduate degree from São Paulo School of Business Administration and earned a masters degree in business administration from Harvard Business School.